Kornimate/medical-research-clean huggingface dataset:
retrospective analysis of the safety and efficacy of hydroxychloroquine in immune thrombocytopenia

Conditions: Immune Thrombocytopenia; Systemic Lupus Erythematosus

Summary: retrospective study of the safety and efficacy of hydroxychloroquine among patients with immune thrombopenia (itp).

hydroxychloroquine (hcq) is usually used in patients with systemic lupus erythematosus (sle) in order to treat mainly arthralgia or skin manifestations of this disease. a few studies have previously shown that hcq could also be useful for treating autoimmune cytopenia and particularly autoimmune thrombopenia associated with sle. in this retrospective study, the investigators have selected patients followed in our center and who have received hcq either for an authentic sle or because they had positive antinuclear antibodies (\> 1/160e on hep2 cells) without a definite sle according to the american college of rheumatology. the main goal of this study is to compare the efficacy of hcq in these two subgroups of patients.

Eligibility criteria:
inclusion criteria: * patients older than 18 years old * immune thrombopenia according to the american society of hematology (ash) guidelines 2011 * positive antinuclear antibodies \> 1/160e on hep2 cells exclusion criteria: * secondary itp (eg hiv, hcv, hbv, lymphoproliferative disorders...)

Keywords: secondary itp hydroxychloroquine systemic lupus erythematosus
long-term follow-up of anal fistula plug

Conditions: Anal Fistula

Summary: aim of the study is to evaluate long-term success rate of biodesign® anal fistula plug for treatment of complex trans-sphincteric anal fistulas.

a prospective series of 95 consecutive patients (30 with inflammatory bowel disease) treated with biodesign® plug in may 2006 - october 2009. all patients were preoperatively assessed by physical examination and 3d endoanal ultrasound, and treated with a loose seton. the patients were assessed by physical examination and 3d endoanal ultrasound at 2 weeks, 3 months, and 6 to 12 months after surgery. long-term follow-up was carried out using a questionnaire, and, when indicated, physical examination and 3d endoanal ultrasound.

Eligibility criteria:
inclusion criteria: * complex transsphincteric anal fistula exclusion criteria: * ano/rectovaginal fistula

Keywords: anal fistula fistula-in-ano surgical plug collagen plug complex anal fistula transsphincteric anal fistula
mechanism of serum prl in the development of mafld

Conditions: Type2 Diabetes; Fatty Liver, Nonalcoholic; Liver Fibrosis

Summary: metabolic associated fatty liver disease (mafld) has currently reached a worldwide epidemic. serum prl levels within or outside physiological range have been found to affect metabolic homeostasis differently. however, the relationship between serum prl and mafld among diabetic patients is unclear. the investigators aimed to explore the association between serum prl and the risk of mafld in patients with type 2 diabetes (t2dm).


Eligibility criteria:
inclusion criteria: * aged 18\~65 years old, * underwent the laboratory tests, hepatic ultrasonography, and valid transient elastography (fibroscan) examination exclusion criteria: * other known chronic liver diseases, such as chronic hepatitis b or c, autoimmune hepatitis, and haemochromatosis * pre-existing active cancer, renal dysfunction, severe liver dysfunction, congestive heart failure or free abdominal fluid * history of hyperthyroidism or hypothyroidism, pituitary diseases, and other types of diabetes * significant alcohol consumption * pregnancy * receiving any therapeutic methods that could lead to liver steatosis or fibrosis, influence the glucolipid metabolism, or prl levels, such as lipid-lowering, and prl-lowering agents (bromocriptine) within 6 months prior to this study.

Keywords: type 2 diabetes metabolic associated fatty liver disease, prolactin
zanamivir versus trivalent split virus influenza vaccine

Conditions: Influenza

Summary: this unblinded pilot study is intended to assess the feasibility of a larger double-blind, randomized control trial. for the larger trial the investigators are interested in understanding the relative benefits of vaccine and antiviral prophylaxis, the risk factors for influenza infection in healthy adults, and in assessing the safety and tolerability of seasonal antiviral prophylaxis in healthcare workers. the pilot study will be assessing the rate of infection with influenza and the rate of adherence to long-term zanamivir in 60 healthy volunteers.

several studies have demonstrated that zanamivir and oseltamivir are effective in preventing influenza infection and illness when used either as prophylaxis after exposure to a household contact with influenza or when taken for several weeks at the height of influenza activity in the general community. however, the longest duration of prophylaxis with neuraminidase inhibitors in two clinical trials, to date, has been six weeks. antiviral medication will likely have an important role in the response to the next influenza pandemic. additionally, there may be indications for use during seasons when the major infecting strain of influenza in not one whose antigen is well covered by the vaccine.

Eligibility criteria:
inclusion criteria: * 18-69 years old as of 01/nov/2008 * have an understanding of the study, agree to its provisions, and give written informed consent prior to study entry * available for follow-up during the study period * if a women of child-bearing years, must meet criteria to prevent pregnancy exclusion criteria: * allergy to any component of influenza vaccine or zanamivir * previous serious adverse event associated with influenza vaccination * receipt of influenza vaccine between 01/mar/2008 and start of study * previous adverse event associated with the use of antiviral medications * expecting to be unable to take zanamivir for more than 72 hours during study period * planning to spend more than 2 consecutive weeks outside canada or more than 100 km from the study site during study period * pregnant, or planning to become pregnant, during study period * breastfeeding, or planning to breastfeed, a child under 12 months of age during study period * receipt of immunoglobulin within six months of study entry * immunocompromising condition or therapy that would be expected to reduce the efficacy of vaccination * plans to receive cytotoxic or radiation therapy during study period * history of cardiovascular or pulmonary disease that has required hospital admission within the past year * history of asthma or other chronic respiratory disease * participating in a trial that will result in the receipt of an investigational medication during the period that zanamivir may be taken (15/nov/2008 to 30/apr/2009)

Keywords: antiviral drugs influenza vaccines
effects of an69 st hemofilter on coagulation during continuous renal replacement therapy in critically ill

Conditions: Critically Ill; Acute Kidney Injury; Septic Shock

Summary: compared with an69 hemofilter, an69 st hemofilter may prolong the time of hemofilter and decrease the quantity of heparin during continuous renal replacement therapy in critically ill.


Eligibility criteria:
inclusion criteria: * age\> 18 years old * admitted to icu and need crrt * anticipated survival time \>72h exclusion criteria: * allergy to hemofilter or heparin * heparin associated thrombocytopenia * pregnancy or lactation * using other anticoagulate drugs

Keywords: hemofilter coagulation crrt critically ill
nudging effect of timer on surgical rub

Conditions: Operation Wound; Infection; Bacterial Infections; Surgical Procedure, Unspecified

Summary: to study whether a device has a nudging effect on the time spend on surgical rub.

the investigators observed the time spend on surgical rub prior to an operation. the investigators do not record names, age, sex or orther features about the health care workers who perform the surgical rub. after 200 observations a device will be attach to the dispenser that might help increase the time spend on the surgical rub in the operathing theather. the investigatos will then make another 200 observations to see if the device cause an increase in the time spend on surgical rub.

Eligibility criteria:
inclusion criteria: • all professional health care workers, who perform surgical ru exclusion criteria: * students and other persons at a hospital, who are not paid to be working at the hospital.
scores in critically ill patients after craniotomy

Conditions: Post-craniotomy; Critical Illness; Mortality; Severity of Illness Scores

Summary: this study planned to review patients admitted to three icu wards at beijing tiantan hospital between 2017 and 2020. it focused on adult patients who had undergone craniotomy and stayed in the icu for more than 24 hours. researchers intended to collect patient information, surgery details, complications, and outcomes from medical records. they also planned to gather routine scoring data used at the hospital and double-check its accuracy. patients would be divided into two groups based on whether they survived or not, and the ability of different scoring systems to predict outcomes would be analyzed. additionally, the study aimed to group patients by the type of surgery and assess how well the scoring systems predicted outcomes for each group.

this study would screen patients admitted to three icu wards at beijing tiantan hospital from 2017 to 2020. adult postoperative craniotomy patients with an icu stay of more than 24 hours would be included. baseline information, surgery-related data, complications, and outcomes would be retrospectively collected. routine scoring assessments conducted at our center would be gathered, and researchers would verify the accuracy of the scoring data. based on patient outcomes, the cohort would be divided into a mortality group and a survival group. the predictive value of different scoring systems for patient outcomes would be evaluated. additionally, patients would be grouped according to surgical indications, and the predictive value of the scoring systems for outcomes in patients with different surgical indications would be assessed.

Eligibility criteria:
inclusion criteria: * patients admitted to the icu wards between 2017 and 2020 * patients underwent craniotomy * patientshad an icu stay of more than 24 hours exclusion criteria: * pregnant or lactating women * patients enrolled in other clinical studies

Keywords: critical ill post-craniotomy apache ii sofa saps ii gcs gcs-p mortality
telemedicine home-based management in patients with chf and type 2 diabetes

Conditions: Chronic Heart Failure; Diabetes Mellitus

Summary: the progressive ageing of the population of industrialized countries is accompanied by a dramatic increase in the prevalence of chronic multi-pathologies. in the general population, hf is associated with a higher prevalence of t2dm compared with patients without hf and with marked regional differences observed in europe and the rest of the world. in clinical trials of chronic hf patients, the prevalence of t2dm is approximately 30% in patients with reduced or preserved ejection fraction and rises to as much as 45% in hospitalized patient registries. a complex drug regimen is often associated with low adherence in patients with hf and t2dm and poor adherence is associated with adverse clinical events. similarly, adherence to recommendations regarding lifestyle changes, such as increasing physical activity, is often limited despite these changes' favourable effects on the patient. therefore, interventions are needed to improve all these factors and optimize adherence. the inclusion of telemedicine (telenursing, telerehabilitation, mhealth) focused on health and correct behaviour can create opportunities to implement customized and scalable solutions in populations at risk. the project will aim to evaluate for patients with chronic diseases with a complex phenotype (heart failure and type ii diabetes mellitus) the effectiveness of a remote surveillance program with particular attention to lifestyle changes.


Eligibility criteria:
inclusion criteria: * inform consent * age ≥ 18 years * documented diagnosis of heart failure, nyha class ii-iii (reduced or preserved ejection fraction without hospitalization in the last 3 months * diagnosis of diabetes mellitus type ii in pharmacological treatment from at least one month * ability to walk without assistive devices * consent to using a device (independently or with the support of a caregiver) for recording the single electrocardiographic trace at home * consent to using the app exclusion criteria: * subjects with poor collaboration * no possibility of using mobile technology * life expectancy of fewer than 6 months * medical issues that preclude participation in the program

Keywords: telemedicine case management mobile technologies (mhealth) physical activities 6-min walking test motivational feedback
kinetics of perioperative circulating dna in cancer surgery

Conditions: Breast Cancer; Prostate Cancer; Colon Cancer

Summary: the aim of this study was to determine the kinetics of perioperative circulating dna in three types of cancer. this first step will enable further studies comparing the potential impact of certain techniques or anesthetic products on cancer surgery.


Eligibility criteria:
inclusion criteria: * the patient must have given their free and informed consent and signed the consent form * the patient must be a member or beneficiary of a health insurance plan * the patient is aged between 18-75 * patient must weigh \>40kg * the patient will receive adjusted carcinological surgery * indication of curative surgery * the patient has already undergone tumoral biopsy prior to surgery * the patient has stage m0 cancer of either colon (right or left colonic adenocarcinoma), prostate (adenocarcinoma) or breast (infiltrating carcinoma) exclusion criteria: * the subject is in a period of exclusion determined by a previous study * the patient is under safeguard of justice * the subject refuses to sign the consent * it is impossible to give the subject informed information * the patient is pregnant, parturient or breast feeding * chronic alcoholism * the patient has received radiotherapy or chemotherapy periopratively * cancer other than colon, breast or prostate * the patient has currently or in the past, had a cancerous lesion * neo-adjuvant therapy (immunotherapy, radiotherapy, chemotherapy) * emergency cancer surgery
early feasibility study (efs) laplace transcatheter tricuspid valve replacement (ttvr) system

Conditions: Tricuspid Regurgitation

Summary: the objective of the study is to assess the safety and technical feasibility of the laplace transcatheter tricuspid valve replacement (ttvr) system

early feasibility (efs), prospective, single-arm, multi-center study to evaluate safety and technical feasibility of the laplace ttvr system in the treatment of severe, symptomatic tricuspid regurgitation patients.

Eligibility criteria:
inclusion criteria: 1. 22 - 90 years of age at the time of the study procedure 2. symptomatic tricuspid regurgitation despite being adequately treated with optimal medical therapy by the local heart team for at least 30 days prior to the time of study consent. 3. severe, massive or torrential tricuspid regurgitation determined by qualifying transthoracic echocardiogram (tte) and/or transesophageal echocardiogram (tee) using the 5-grade classification. 4. candidate felt suitable for transcatheter tricuspid valve replacement as determined by the local heart team and confirmed by the patient selection committee. for patients with pre-existing trans-tricuspid pacemaker or icd leads, the local heart team shall include an electrophysiologist. 5. subject or legally authorized representative has provided informed consent and agrees to return for all required post-procedure follow-up visits exclusion criteria: 1. estimated life expectancy of less than 12 months 2. pvr \>5 wood units 3. echocardiographic evidence of severe right ventricular dysfunction 4. severe aortic, mitral and/or pulmonic valve stenosis and/or regurgitation requiring treatment 5. presence of significant congenital heart disease including but not limited to hemodynamically significant atrial septal defect, rv dysplasia, and arrhythmogenic rv. 6. any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery, within last 30 days. implant or revision of any rhythm management device (crt or crt-d) or implantable cardioverter-defibrillator or leadless pacemaker within 90 days prior to the study procedure 7. stroke or other major cerebrovascular event within 90-days prior to index procedure 8. untreated clinically significant coronary artery disease requiring revascularization, recent (within last 30 days) acute coronary syndrome or myocardial infarction. 9. bleeding disorders including thrombocytopenia or platelet count \ 700,000 /mm3) 10. current or planned pregnancy within next 12 months for women of childbearing potential 11. active or recent endocarditis within last 90 days or, sepsis/ other systemic infection requiring oral or intravenous antibiotics within last 30 days 12. presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements. any patient considered to be vulnerable. 13. left ventricular ejection fraction (lvef) \< 30%
a phase iiib study to compare entecavir plus tenofovir vs. adefovir added to continuing lamivudine therapy in adult patients with lamivudine-resistant hepatitis b infection

Conditions: Chronic Hepatitis B

Summary: the purpose of this clinical research study is to find out whether a combination of entecavir (etv) plus tenofovir (tnf) works better against hepatitis b virus than adefovir (adv) added to continuing lamivudine (lvd) therapy in patients whose hepatitis b virus (hbv) is resistant against lamivudine. the safety of this treatment will also be studied.


Eligibility criteria:
inclusion criteria: * chronic hbv infection * history of lamivudine (lvd) treatment, and lamivudine resistance (lvdr), receiving lvd at screening visit * compensated liver function * hbv dna ≥ 172,000 iu/ml * hepatitis b e-antigen (hbeag)-positive or hbeag-negative exclusion criteria: * evidence of decompensated cirrhosis * coinfection with human immunodeficiency virus (hiv), hepatitis c virus (hcv), or hepatitis d virus (hdv) * recent history of pancreatitis * serum alpha fetoprotein \> 100 ng/ml * except lamivudine, any prior therapy with nucleoside or nucleotide analogue antiviral agents with activity against hepatitis b
comparing safety and efficacy of combigan® and lumigan® with lumigan® alone in glaucoma or ocular hypertension subjects treated with xalatan®

Conditions: Glaucoma; Ocular Hypertension

Summary: comparing safety and efficacy of combigan® and lumigan® with lumigan® alone in glaucoma or ocular hypertension subjects treated with xalatan®.


Eligibility criteria:
inclusion criteria: * diagnosed with glaucoma or ocular hypertension. * visual acuity 20/100 or better in both eyes exclusion criteria: * any active ocular disease * history of any intraocular surgery or glaucoma laser surgery within 3 months * contraindication to pupil dilation * use of topical, periorbital, intravitreal, or systemic steroid within 3 months
utilizing neural signatures and virtual reality to advance dbs programming

Conditions: Parkinson Disease; DBS; Deep Brain Stimulation; Freezing of Gait; Virtual Reality

Summary: the project uses virtual reality technology to recreate situations that cause freezing of gait in individuals with parkinson's disease. individuals who underwent deep brain stimulator (dbs) surgery for parkinson's disease will walk through a virtual reality environment while brain signals are recorded from the dbs device. the goal is to better understand what occurs in the brain during freezing of gait.

falls related to problems with posture and walking as well as freezing of gait (fog) occur in nearly 80% of people with parkinson's disease (pd). despite falls occurring in the daily lives of people with pd, it is difficult to produce fog episodes in a doctor's office or other clinical setting. we will therefore use virtual reality to create an environment that can consistently produce fog episodes in people with pd. by purposely producing fog while people are wearing equipment that monitors brain activity, we can see where in the brain fog is triggered. study participants will be asked to wear a virtual reality (vr) headset and heart rate monitor and walk on a treadmill that permits users to start, stop, and turn, allowing them to naturally walk through a virtual environment. we will record the activity from the dbs system while participants perform the tasks. participants will also complete clinical assessments of pd, a fog questionnaire and cognitive tests that include naming objects and recalling items from a list.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of idiopathic pd * undergoing scheduled surgery for bilateral stn-dbs at a cleveland clinic facility or previously undergone stn-dbs surgery with the medtronic percept brainsense dbs system * self-reported response of one or greater on question #3 of the freezing of gait questionnaire (fog-q) * ability to walk independently for a minimum of 10 minutes * ability to provide informed consent exclusion criteria: * neurological disease other than pd, such as stroke or multiple sclerosis * musculoskeletal impairment that affects one's ability to ambulate * presence of active and untreated psychiatric symptoms meeting diagnostic and statistical manual of mental disorders-4th edition (dsm-iv) criteria for axis-i disorder. depression and anxiety are very common in patients with parkinson's disease and are often mitigated as part of routine care. depression and anxiety will not preclude study participation * cognitive impairment meeting diagnostic and statistical manual of mental disorders-4th edition (dsm-iv) criteria for dementia on formal neuropsychological evaluation * current alcohol or substance abuse * hearing or visual impairment precluding vr use * lack of fluency in english which may invalidate certain tests
neoadjuvant chemotherapy response in metaplastic carcinoma of triple negative breast cancer

Conditions: Metaplastic Breast Carcinoma

Summary: prospective study for response of neoadjuvant chemotherapy in metaplastic carcinoma of triple negative breast cancer

vimentin/pan ck staining will be performed on tissues of patient who visited seoul national university hospital and were diagnosed with triple negative breast cancer and decided to perform neoadjuvant chemotherapy under clinical judgement. histologically determined to be a metaplastic breast cancer or tested positive for vimentin/pan ck patients decides as the metaplastic breast cancer. they evaluate the response rate of the neoadjuvant chemotherapy. patients with vimentin/pan ck negative are diagnosed with non-metaplastic breast cancer and this group also confirms the response rate of neoadjuvant chemotherapy. the group of metaplastic breast cancer will enroll 50 people, and the group of non-metaplastic breast cancer will enroll 100 people.

Eligibility criteria:
inclusion criteria: * over 20 years old * patients with triple negative breast cancer diagnosed seoul national university hospital * patients who decided to perform neoadjuvant chemotherapy under clinical judgement exclusion criteria: * not applicable